Overview AI is speeding up drug discovery by analyzing large biological and chemical data in a short time.Deep learning and AI systems help design new drug mole ...

Changes in the political climate of the United States are spilling into scientific research. While many past administrations, of both parties, supported and funded science funding and education, the ...

Automation and AI are revolutionizing the pharmaceutical industry, optimizing technical development and enabling faster, more ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Traditionally, developing a new drug takes many years and requires a massive financial investment, often involving significant risk and a high likelihood of failure. AI models trained on extensive ...

Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...

Amid the surging wave of innovation in China's biopharmaceutical industry, a decade is long enough to witness the full evolution of a sector-from its initial emergence and growth to fundamental ...

The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...